• Materialise published its annual report for fiscal 2025, highlighting steady group revenue despite currency headwinds and weaker prototyping demand.
• Medical delivered record growth, topped 700,000 cumulative treated patients since founding, reached more than 70,000 patients in 2025.
• Software advanced shift to cloud subscriptions, rolled out CO-AM product tiers, expanded automation offering with CO-AM Brix.
• Manufacturing continued repositioning toward serial production in certified end-markets, reporting progress in aerospace and defense programs.
• Management reaffirmed focus on capital markets access following November Euronext Brussels listing, maintained shareholder returns via EUR 30 million ADS buyback program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Materialise NV published the original content used to generate this news brief on May 15, 2026, and is solely responsible for the information contained therein.